More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$149565927
EPS
-1.71
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.786287
Previous close
$5.57
Today's open
$5.50
Day's range
$5.37 - $5.61
52 week range
$3.71 - $8.74
show more
CEO
Shalabh Gupta
Employees
23
Headquarters
Mountain View, CA
Exchange
NASDAQ Capital Market
Shares outstanding
27393027
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
GlobeNewsWire • Jul 13, 2026

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.
GlobeNewsWire • Jul 11, 2026

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC. (UNCY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to discuss your.
Business Wire • Jul 8, 2026

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC. (UNCY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Business Wire • Jul 8, 2026

Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC. (UNCY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On June 30, 2026, Unicycive disclosed that the FD.
Business Wire • Jul 7, 2026

UNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened?
GlobeNewsWire • Jul 7, 2026

Unicycive Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Boston, Massachusetts--(Newsfile Corp. - July 6, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
Newsfile Corp • Jul 6, 2026

Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
GlobeNewsWire • Jul 2, 2026

UNCY INVESTIGATION ALERT: Investors Who Lost Money in Unicycive Therapeutics, Inc. Should Contact Block & Leviton
Boston, Massachusetts--(Newsfile Corp. - July 2, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
Newsfile Corp • Jul 2, 2026

UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Lett.
Business Wire • Jul 1, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Unicycive Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.